| Literature DB >> 29137379 |
Bo Yu1,2, Qiong Du1,2, Huan Li1,2, Hong-Yue Liu1,2, Xuan Ye1,2, Bin Zhu1,2, Qing Zhai1,2, Xin-Xiang Li1,3.
Abstract
In this study, we investigated the diagnostic potential of serum exosomal colorectal neoplasia differentially expressed (CRNDE-p) long coding RNA and microRNA-217 in colorectal carcinoma (CRC). We detected high CRNDE-p and low miR-217 levels in exosomes released by multiple CRC cell lines into culture media as well as in sera from CRC xenograft mice and CRC patients. Conversely, we observed lower CRNDE-p and higher miR-217 levels in serum exosomes from post-chemotherapy than from pre-chemotherapy patient samples. The area under curve (AUC) value for the serum exosomal CRNDE-p and miR-217 combination was higher than CRNDE-p or miR-217 alone. Moreover, high CRNDE-p and low miR-217 serum exosomal levels correlated with advanced clinical stages (III/IV), tumor classification (T3/T4), and lymph node or distant metastasis. Thus combined evaluation of serum exosomal CRNDE-p and miR-217 levels show diagnostic and prognostic potential for CRC patients.Entities:
Keywords: CRNDE-p; colorectal carcinoma; exosome; miR-217
Year: 2017 PMID: 29137379 PMCID: PMC5663551 DOI: 10.18632/oncotarget.19407
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Characterization of serum exosomes
(A) Representative TEM image shows enriched serum exosomes as indicated by the arrow (scale bar: 100 nm; HV = 80.0 kv); (B) Representative western blots showing Hsp-70, CD63 and TSG101 levels in purified serum exosomes from CRC patients (lanes 1–2) and exosome-depleted supernatant (lanes 3–4).
Figure 2Differential expression of exosomal CRNDE-p and miR-217 from human CRC cell lines and CRC mouse xenograft model
(A) Relative expression of CRNDE-p and miR-217 in exosomes isolated from the culture supernatants of normal human colon mucosal epithelial cell line NCM460 and human colorectal cancer cell lines, namely, HT-29, SW480, HCT-116, SW620, LoVo, SW48, DLD-1, Caco2 and HT-15 lines. (B) Northern Blot is used to evaluate the expression of CRNDE-p and miR-217 in exosomes isolated from the mentioned cells. (C) Relative expression of CRNDE-p and miR-217 in exosomes isolated from the culture supernatants on days 1–3 of normal human colon mucosal epithelial cell line NCM460 and human colorectal cancer cell lines, namely, HT-29, SW480, HCT-116, SW620, LoVo, SW48, DLD-1, Caco2 and HT-15 lines. (D) Representative image of tumors from xenograft mice at 5 weeks after HCT-116 cells’ injection. Relative expression of serum exosomal CRNDE-p and miR-217 in CRC xenograft mice and sham controls (n = 6). Note: The expression of CRNDE-p and miR-217 were quantified relative to cel-miR-39 by qRT-PCR.
Figure 3Differential expression of exosomal CRNDE-p and miR-217 in serum exosomes from CRC patients, adenoma patients and health volunteers and ROC curve analysis
(A) Relative expression of serum exosomal CRNDE-p and miR-217 in CRC patients (n = 410), adenoma patients (n = 58) and healthy volunteers (n = 175). (B) Relative levels of serum exosomal CRNDE-p and miR-217 in CRC patients before (Pre-chemotherapy) and 21 days after chemotherapy (Post-chemotherapy). (C) Receiver-operating characteristic (ROC) curves of serum exosomal CRNDE-p, miR-217, CEA and combined CRNDE-p/miR-217 or CRNDE-p/CEA levels in CRC patients and adenoma patients.
Correlations of clinicopathological parameters and expression level of CRNDE and miR-217 in patients with CRC (n = 410)
| Varibles | No. of patient | No. of patient (%) | CRNDE expression (Mean ± SEM) | miR-217 expression (Mean ± SEM) | ||
|---|---|---|---|---|---|---|
| Ages (years) | ||||||
| < 59 | 206 | 50.24 | 21.14 ± 3.58 | 0.6672 | 3.17 ± 0.22 | 0.2765 |
| ≥ 59 | 205 | 50.00 | 23.58±4.40 | 2.72 ± 0.35 | ||
| Gender | ||||||
| Male | 252 | 61.46 | 22.01 ± 3.02 | 0.8418 | 2.85 ± 0.31 | 0.5488 |
| Female | 158 | 38.54 | 22.93 ± 3.26 | 3.12 ± 0.28 | ||
| Localization | ||||||
| Rectum | 181 | 44.15 | 22.74 ± 1.85 | 0.8131 | 2.75 ± 0.28 | 0.4307 |
| Colon | 229 | 55.85 | 22.07 ± 2.05 | 3.11 ± 0.34 | ||
| T stage | ||||||
| T1–T2 | 204 | 49.76 | 15.65 ± 1.77 | 0.0033 | 3.74 ± 0.42 | 0.043 |
| T3–T4 | 206 | 50.24 | 26.10 ± 3.05 | 2.17 ± 0.35 | ||
| Regional lymph node metastasis | ||||||
| Negative | 235 | 57.32 | 16.52 ± 2.22 | 0.0007 | 3.47 ± 0.36 | 0.011 |
| Positive | 175 | 42.68 | 30.21 ± 3.59 | 2.26 ± 0.26 | ||
| Distant metastasis | ||||||
| No | 305 | 74.39 | 20.77 ± 1.36 | 0.0293 | 3.25 ± 0.33 | 0.0479 |
| Yes | 105 | 25.61 | 26.99 ± 2.81 | 2.09 ± 0.27 | ||
| Clinical stage | ||||||
| I–II | 200 | 48.78 | 18.85 ± 2.95 | 0.0436 | 3.58 ± 0.29 | 0.0038 |
| III–IV | 211 | 51.46 | 25.59 ± 2.05 | 2.34 ± 0.31 |